Apolipoprotein C-III from Human Plasma (Solution)

<strong>Apolipoprotein C-III from Human Plasma (Solution)</strong>_x000D_ <strong>Catalog number:</strong> B2016526_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 50 µg_x000D_ <strong>Molecular Weight or Concentration:</strong> 8.75 kDa_x000D_ <strong>Supplied as:</strong> Solution_x000D_ <strong>Applications:</strong> a molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> -80°C_x000D_ <strong>Keywords:</strong> Apolipoprotein C-III, Apo-CIII, ApoC-III, Apo C3_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Koska J, Furtado J, Hu Y, Sinari S, Budoff MJ, Billheimer D, Nedelkov D, McClelland RL, Reaven PD. Plasma proteoforms of apolipoproteins C-I and C-II are associated with plasma lipids in the Multi-Ethnic Study of Atherosclerosis J Lipid Res. 2022 Sep;63(9):100263._x000D_ 2: Ferrell RE, Kamboh MI, Majumder PP, Valdez R, Weiss KM. Genetic studies of human apolipoproteins. XIII. Quantitative polymorphism of apolipoprotein C-III in the Mayans of the Yucatán Peninsula Hum Hered. 1990;40(3):127-35._x000D_ 3: Tornoci L, Scheraldi CA, Li X, Ide H, Goldberg IJ, Le NA. Abnormal activation of lipoprotein lipase by non-equilibrating apoC-II: further evidence for the presence of non-equilibrating pools of apolipoproteins C-II and C-III in plasma lipoproteins J Lipid Res. 1993 Oct;34(10):1793-803._x000D_ 4: Smit NPM, Romijn FPHTM, van Ham VJJ, Reijnders E, Cobbaert CM, Ruhaak LR. Quantitative protein mass-spectrometry requires a standardized pre-analytical phase Clin Chem Lab Med. 2022 Sep 8;61(1):55-66._x000D_ 5: Massey JB, Pownall HJ. Surface properties of native human plasma lipoproteins and lipoprotein models Biophys J. 1998 Feb;74(2 Pt 1):869-78._x000D_ 6: McConathy WJ, Gesquiere JC, Bass H, Tartar A, Fruchart JC, Wang CS. Inhibition of lipoprotein lipase activity by synthetic peptides of apolipoprotein C-III J Lipid Res. 1992 Jul;33(7):995-1003._x000D_ 7: Sinari S, Koska J, Hu Y, Furtado J, Jensen MK, Budoff MJ, Nedelkov D, McClelland RL, Billheimer D, Reaven P. Apo CIII Proteoforms, Plasma Lipids, and Cardiovascular Risk in MESA Arterioscler Thromb Vasc Biol. 2023 Aug;43(8):1560-1571._x000D_ 8: Liu H, Labeur C, Xu CF, Ferrell R, Lins L, Brasseur R, Rosseneu M, Weiss KM, Humphries SE, Talmud PJ. Characterization of the lipid-binding properties and lipoprotein lipase inhibition of a novel apolipoprotein C-III variant Ala23Thr J Lipid Res. 2000 Nov;41(11):1760-71._x000D_ 9: Demuth K, Myara I, Chappey B, Vedie B, Pech-Amsellem MA, Haberland ME, Moatti N. A cytotoxic electronegative LDL subfraction is present in human plasma Arterioscler Thromb Vasc Biol. 1996 Jun;16(6):773-83._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/3080947">10: Alaupovic P, Wang CS, McConathy WJ, Weiser D, Downs D. Lipolytic degradation of human very low density lipoproteins by human milk lipoprotein lipase: the identification of lipoprotein B as the main lipoprotein degradation product Arch Biochem Biophys. 1986 Jan;244(1):226-37. </a>_x000D_ _x000D_ <strong>Products Related to Apolipoprotein C-III from Human Plasma (Solution) can be found at</strong> <a href="https://moleculardepot.com/product-category/Biofluids/"> Biofluids</a>